Great presentation by Olga Kantor MD, MS, FACS #ASCO24 - importance of providing support to marginalized groups to optimize cancer care Dana-Farber’s Breast Oncology Center Brigham and Women’s Department of Surgery

ADCs have shortened distances between scientists globally, with the partnership between West & East leading to major advancements in oncology. Glad to push this collaboration forward through the monthly 🌎Global Young JC- today, with great Trop2 lectures by Drs Punie, Fan & Shi!

Press Release: the #CAPItello290 trial of 1L paclitaxel +/- capivasertib in advanced TNBC did not meet the dual primary endpoints of OS in the overall population or in patients with AKT-pathway-mutant disease. astrazeneca.com/media-centre/p…

Great presentations by Paolo Tarantino Ada Waks and Dr Sarah Sammons in the OncLive.com Dana-Farber’s Breast Oncology Center updates in breast cancer

More outstanding talks reviewing the most recent #bcsm data at the Dana-Farber’s Breast Oncology Center OncLive.com summit 👏👏👏 Sara Tolaney Erica Mayer Filipa Lynce, MD, FASCO Antonio Giordano, MD PhD

Tumor-Infiltrating Lymphocytes in Stage I TNBC Untreated With Chemotherapy 💥Patients with pT1c TNBC tumors and sTIL levels ≥50% had a 10-year survival of 95% without chemotherapy, increasing to 98% with sTIL levels ≥75% OncoAlert jamanetwork.com/journals/jamao…

Can ADCs help prevent BC relapse with maintained QoL? Glad to share the final analysis of ATEMPT, out in JCO: among 383 pts with stage I HER2+ BC receiving T-DM1, 5y iDFS was 97%, with 3 (<1%) distant events. Deep dive in the study & biomarkers below🧵1/10 ascopubs.org/doi/10.1200/JC…

Excellent review on checkpoint inhibition for early-stage hormone receptor-positive #BreastCancer from Ilana Schlam Chiara Corti Dr Sarah Sammons Dr. E Mittendorf Sara Tolaney Check it out here: tandfonline.com/doi/full/10.10…

Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO? If you have 20 minutes for a read this week, make sure not to miss this Journal of Clinical Oncology commentary by MarleenKokLab et al, full of thought provoking reflections on the path forward in treating TNBC ascopubs.org/doi/pdf/10.120…

New study led by Dr. Rachel Freedman just published in Annals of Oncology looking at Neratinib and Ado-Trastuzumab-Emtansine for Pre-treated and Untreated HER2+ #BreastCancerBrainMetastases Rachel Freedman, MD, MPH Nancy Lin, MD Heather Parsons Beverly Moy Dario Trapani Adam Brufsky pubmed.ncbi.nlm.nih.gov/38977064/

The FDA has granted fast track designation to the ex vivo gene-modified autologous CAR-monocyte therapy, CT-0525, for use as a potential therapeutic option in patients with HER2-overexpressing solid tumors. U.S. FDA #oncology onclive.com/view/fda-award…

Incredibly important observation Romualdo Barroso, MD PhD and colleagues! Supports Oxford overview conclusion that dose dense administration of ANY regimen confers clinical advantage. Congratulations!

Check out our ASCO Daily News editorial “IMpassion132: Learning From Immunotherapy’s Failures in Early Relapsing Triple-Negative Breast Cancer” at dailynews.ascopubs.org/do/impassion13… Chiara Corti Dana-Farber’s Breast Oncology Center

Exciting results; BCI was able to show who might benefit from ovarian ablation in the adj setting. A large step forward to spare tons of toxicity from young pts!

IMpassion132, a phase 3 trial of chemo + ICI for early relapsing triple-negative #BreastCancer, was a negative study that provided informative results for an understudied population. Chiara Corti & Ilana Schlam dig into the results for #ASCODailyNews: dailynews.ascopubs.org/do/impassion13… #bcsm

Now available: new ASCO guideline clinical insights on targeted therapies, sequencing strategies, and beyond in metastatic hormone-receptor positive #BreastCancer: brnw.ch/21wMbqE #bcsm #JCOOP

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

1) Imlunestrant at RP2D of 400mg- mPFS 7.2 mo 2) Imlunestrant + Abemaciclib in CDK naive patients mPFS19.2 mo 3)Imlunestrant + Everolimus 16 mo, Imlunestrant + Alpelisib 9 mo- no DDI or new safety signals.Activity in combination regardless of ESR1m. Await EMBER 3 results now